CagriSema
FDA approvedAmylin meets GLP-1 — dual mechanism that addresses what semaglutide alone misses.
Mechanism
Amylin / GLP-1 dual mechanism. Amylin meets GLP-1 — dual mechanism that addresses what semaglutide alone misses. For full mechanism, dosing protocol, and stacking guidance, ask the AI Advisor or open the compound in-app.
Peer-Reviewed Studies (2)
CagriSema in Adults with Overweight or Obesity (REDEFINE-1)
22.7% mean weight loss at 68 weeks vs ~17% on semaglutide alone.
PubMed PMID 39908411 →Cagrilintide as a Weight Management Therapy
Phase 2 monotherapy data established cagrilintide efficacy independent of GLP-1.
PubMed PMID 33894838 →